Tucatinib/tucatinib latest quotation and market application overview

Tucatinib/Tucatinib (Tucatinib) is an innovative anti-cancer drug that has become an important drug for the treatment of specific types of hormone receptor-positive breast cancer since its approval on the market. This breast cancer has metastasized and spread to other parts of the patient's body, and surgery is no longer a viable option for adult patients who have been through at least one round of other chemotherapy drugs. In addition, tucatinib has also shown efficacy in treating a certain type of colorectal cancer that has metastasized when used in combination with trastuzumab, providing new treatment opportunities for patients whose disease has not improved or worsened after other chemotherapy treatments.

Tucatinib is a type of kinase inhibitor that inhibits the proliferation of cancer cells by blocking the function of abnormal proteins. At present, although the original drug tucatinib has not yet been launched in China and therefore cannot enter the medical insurance system, it has been sold in overseas markets. Specifically, the European version of the original tucatinib drug is 150mg*60 tablets, and the price per box may be as high as more than 70,000 yuan. Of course, this price will be affected by exchange rate fluctuations. Obviously, this is a significant financial burden for many patients.

Fortunately, generic versions of tucatinib have appeared in overseas markets, such as those produced by Bangladeshi pharmaceutical companies.The price of the 150mg*30 tablet product is only about 4,000 yuan, which may also fluctuate due to exchange rates. Compared with original drugs, generic drugs are significantly more affordable and their drug ingredients are highly consistent with original drugs, providing patients with a more economical treatment option. For more information on overseas drug prices and related information, please consult Yaode Medical Consultant.